AOAnass Oukhdouch

Anass Oukhdouch

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Anass Oukhdouch has a total of 21 co-authors. Here are the top co-authors by number of shared publications:

  • Basma Zinbi

    Anatomic Pathology Department, University Hospital Mohammed VI, Marrakech, Morocco

    2 shared publications
  • Hanane Rais

    Morphoscience Research Laboratory, Faculty of Medicine and Pharmacy, Cadi Ayyad University, Marrakech 40000, Morocco

    2 shared publications
  • Souad Sellami

    Anatomic Pathology Department, University Hospital Mohammed VI, Marrakech, Morocco

    2 shared publications
  • Youssef Nadir

    Biological Engineering Laboratory, Faculty of Science and Technology, Sultan Moulay Slimane University, Beni Mellal 23000, Morocco

    2 shared publications
  • Abdelmalek Hakmaoui

    Laboratory of Biopathology, Center of Clinical Research, Mohammed VI University Hospital Center, Marrakech, Morocco

    1 shared publication
  • Basma Zinbi

    Anatomic Pathology Department, Biopathology Laboratory, Clinical Research Center, University Hospital Mohammed VI, Marrakech 40000, Morocco

    1 shared publication

Latest Publications

  • Open Access

    Rewiring the Glioma Ecosystem: Glial–Tumor Crosstalk, Immune Evasion, and Therapeutic Opportunities

    by Anass Oukhdouch, Maria Dref, Youssef Nadir, Hayat Bouighajd, Wijdane Ait Marzouka, Imane Elbah, Basma Zinbi, Souad Sellami, Fatima Ezzahra Hazmiri, Hanane Rais

    Glioblastoma (GBM), classified as grade 4 of high-grade glioma (HGG) under the 2021 World Health Organization (WHO) Classification of Central Nervous System Tumors (WHO CNS-2021), is the most aggressive primary brain tumor in adults. However, with maximal surgical resection, concurrent radiotherapy, and temozolomide (TMZ) chemotherapy, a median patient survival is still between 14 and 16 months. The persistent failure of current treatments is not only traceable to the molecular complexity of tumor cells but is fundamentally shaped by the tumor microenvironment (TME), in which non-neoplastic cells collectively constitute up to half of the total tumor mass. Reactive astrocytes, microglia, tumor-associated macrophages (TAMs), and oligodendrocyte precursor cells (OPCs) are no longer regarded as passive bystanders but as active architects of tumor progression, immune evasion, and therapy resistance. In this comprehensive review, we systematically describe the molecular mechanisms of glial–tumor crosstalk across all three major glial cells. Reactive astrocytes sustain tumor invasion and chemoresistance through connexin-43 gap junctions, bidirectional IL-6/JAK-STAT3 paracrine signaling, and extracellular vesicle-mediated oncogenic reprogramming. Microglia and TAMs undergo profound transcriptional reprogramming via PI3K/Akt/mTOR and CSF-1R signaling, adopting immunosuppressive states that exclude cytotoxic T cells, maintain glioma stem cell (GSC) niches, and drive angiogenesis. OPCs are now underexplored, accumulate at the tumor border, and cooperate with macrophages via Notch and Wnt/β-catenin pathways to establish a therapy-resistant GSC niche at the precise site of post-surgical recurrence. We further address glial–glial interactions as an independent regulatory layer and integrate recent spatial transcriptomic (ST) results revealing a structured, multi-glial niche that governs drug penetration. Finally, we critically evaluate emerging therapeutic strategies targeting these glial–tumor interfaces, including CSF-1R inhibitors, STAT3 modulators, CD47/SIRPα blockades, and engineered extracellular vesicle-based delivery systems. Understanding and targeting the glial ecosystem is an inseparable new field to explore.

  • Open Access

    The EGR1-FOS Transcriptional Axis in Liver Fibrosis: An Integrated Bioinformatic Analysis of Disease Progression and Shared Molecular Signatures in Cirrhosis

    by Youssef Nadir, Hicham Esselmani, Anass Oukhdouch, Habiba Nechchadi, Rahma Ennadi, Mohammed Amine Lkousse, Issame Farouk, Mustapha Najimi, Mohamed Merzouki

    Background: Liver fibrosis arises from chronic liver injury and remains a major clinical challenge due to its progression toward cirrhosis and hepatocellular carcinoma, as well as the absence of approved antifibrotic therapies. This study aimed to characterize the transcriptomic behavior of the EGR1-FOS axis in liver fibrosis and its evolution into hepatocellular carcinoma, and to identify genes shared between liver fibrosis and cirrhosis. Methods: An integrated bioinformatics approach was applied to GEO transcriptomic datasets. Differentially expressed genes in hepatic fibrosis were identified using GSE139602, GSE84044, and GSE49541, with GSE62232 as control when needed, while GSE14323 and GSE89377 were used to detect genes common with cirrhosis. GEPIA, TIMER, and TISCH2 were used to assess the involvement of the EGR1-FOS axis in hepatocellular carcinoma. External validation of EGR1 expression dynamics and its coregulation with FOS was performed using the GSE135251 dataset. Results: Eleven hub genes were identified, with emphasis on the EGR1-FOS axis. EGR1 expression fluctuated across liver fibrosis etiologies, whereas FOS was predominantly downregulated. A strong correlation between EGR1 and FOS (r = 0.77) was observed, remaining stable across fibrosis stages (all p < 0.001) and in hepatocellular carcinoma (r = 0.698, p = 1.81 × 10−55). Despite overall downregulation, both genes increased progressively with advancing fibrosis (EGR1: p = 0.0008–0.0035; FOS: p = 0.0001–0.0188). Four genes were shared between fibrosis and cirrhosis (SOX9, CD24, CXCR4, and CYP2C19). Conclusions: The EGR1-FOS axis acts as a dynamic regulator of liver fibrosis and its progression, and both this axis and the four shared genes identified may serve as valuable biomarkers and potential therapeutic targets.

  • Open Access

    EGFR gene amplification in IDH-wildtype glioblastomas: an integrative bioinformatic and histopathological analysis using immunohistochemistry and fluorescence in situ hybridization

    by Anass Oukhdouch, Basma Zinbi, Souad Sellami, Hanane Rais

    Background Glioblastoma multiforme (GBM) is the most aggressive primary brain tumor in adults, characterized by marked histopathological features such as high proliferative activity, mitoses, necrosis, and microvascular proliferation (MVP), as well as extensive molecular heterogeneity. Among key molecular alterations, EGFR amplification and MGMT promoter methylation hold significant diagnostic and prognostic relevance. In this study, we performed a comprehensive bioinformatic analysis of EGFR and conducted a correlation analysis of EGFR amplification in a cohort of 19 GBM samples using standard fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC). These results were further correlated with established molecular hallmarks of glioblastoma. Methods We analyzed mRNA expression profiles of EGFR family genes using publicly available datasets from the Gene Expression Omnibus (GEO) and Chinese Glioma Genome Atlas (CGGA) databases. Additionally, we utilized multiple online bioinformatics platforms, including GEPIA, TIMER, TISIDB repository, cBioPortal, Metascape, and GeneMANIA, to explore the expression patterns, immune cell infiltration, correlation of EGFR amplification with immunomodulatory and prognostic significance of the EGFR family in glioblastoma. EGFR amplification and protein expression were assessed using fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC), respectively. MGMT promoter methylation was determined by methylation-specific qPCR (MS-qPCR). Results Bioinformatic analyses revealed that EGFR and ERBB2 were overexpressed and associated with poor prognosis, while ERBB3 and ERBB4 exhibited decreased expression in GBM compared to normal brain tissue. Immune infiltrating level correlation of EGFR family, revealed that EGFR and ERBB4 expression were positively correlated with various immune cell infiltrates in glioblastoma, particularly CD8 + T cells, macrophages, and B cells. Additionally, EGFR expression was negatively correlated with key co-stimulatory molecules including CD28, CD40, CD70, and IL2RA, no significant associations were found with classical immune checkpoints such as PD-L1 and CTLA-4, though EGFR was inversely correlated with TGFBR1. Subtype analysis showed elevated EGFR expression in Classical-like and Mesenchymal-like GBM subtypes, and a trend toward higher levels in the lymphocyte-depleted immune subtype. Genomic analysis revealed that EGFR family alterations in 49% of GBM cases, with EGFR amplification being the most frequent and linked to poorer overall survival. Enrichment and the PPI network analyses demonstrated that the EGFR family is deeply involved in tumorigenic pathways, particularly PI3K/AKT signaling, integrin interactions, and growth factor receptor cascades. We found that EGFR amplification was detected in 36.84% of cases and was significantly associated with EGFR protein overexpression (IHC score 3+). MGMT promoter methylation was present in 47.4% of cases. No significant association was found between EGFR amplification and MGMT methylation, ATRX, or p53 status. Conclusion Our integrative bioinformatics and histopathological analyses highlight EGFR as a central oncogenic driver and potential immunomodulatory factor in GBM. EGFR amplification correlates with poor prognosis, immune dysregulation, underscoring its utility as both a diagnostic biomarker and a potential therapeutic target in GBM management.


  • Open Access

    Detection of O6-methylguanine-DNA methyltransferase gene methylation status in IDH-wild type glioblastomas using methylation-specific qPCR: a first report from Morocco

    by Anass Oukhdouch, Abdelmalek Hakmaoui, Basma Zinbi, Souad Sellami, Bouighajd Hayat, Hanane Rais

    We tried, through this work, to highlight the first detection of the methylation status of the O6-methylguanine-DNA methyltransferase gene (MGMT) promoter in IDH-wild-type glioblastomas with observation of the expression of IDH1, ATRX, and P53 by immunohistochemistry. Across eight formalin-fixed, paraffin-embedded tissue blocks (FFPE) from glioblastoma patients, we collected tumor tissue samples. We examined the methylation status of the MGMT gene promoter using a real-time methylation-specific PCR technique (MS-qPCR). In addition, we observed the molecular alterations caused by mutations in IDH1, ATRX, and p53 using immunohistochemistry (IHC). All cases studied had a wild-type form of IDH1, loss of ATRX expression was observed in five samples. In two cases, the mutated form of p53 was expressed. The level of p53 expression ranged from intense (>80% of tumor cells) to weak (>10% of tumor cells), and less than 10% labeling was considered negative. In our study, when analyzing the methylation profiles of the MGMT gene promoter, we found that two cases, specifically sample 2 and sample 5, exhibited positive methylation. Sample 2 had a methylation rate of 6.8%, while sample 5 showed a methylation rate of 27%. In contrast, sample 6 had a methylation rate of 0.05%, which fell below the established methylation cutoff point of 0.6%. Therefore, sample 6 was considered negatively methylated because its methylation rate was significantly lower than the established threshold. This study identifies MGMT promoter methylation in a subset of glioblastomas IDH-wild-type. These findings highlight the molecular diversity of glioblastomas and suggest potential targets for tailored therapeutic strategies.